153 related articles for article (PubMed ID: 29928505)
41. Inflammation as a chemoprevention target in asbestos-induced malignant mesothelioma.
Kadariya Y; Sementino E; Shrestha U; Gorman G; White JM; Ross EA; Clapper ML; Neamati N; Miller MS; Testa JR
Carcinogenesis; 2022 Dec; 43(12):1137-1148. PubMed ID: 36355620
[TBL] [Abstract][Full Text] [Related]
42. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
[TBL] [Abstract][Full Text] [Related]
43. Pathogenesis of malignant pleural mesothelioma.
Jaurand MC; Fleury-Feith J
Respirology; 2005 Jan; 10(1):2-8. PubMed ID: 15691231
[TBL] [Abstract][Full Text] [Related]
44. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
45. Identification of calretinin and the alternatively spliced form calretinin-22k in primary pleural mesotheliomas and in their metastases.
Schwaller B; Celio MR; Doglioni C
Anticancer Res; 2004; 24(6):4003-9. PubMed ID: 15736446
[TBL] [Abstract][Full Text] [Related]
46. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
47. Establishment and characterization of CRISPR/Cas9-mediated NF2
Wahiduzzaman M; Karnan S; Ota A; Hanamura I; Murakami H; Inoko A; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y
Cancer Sci; 2019 Jan; 110(1):180-193. PubMed ID: 30417500
[TBL] [Abstract][Full Text] [Related]
48. SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells.
Pietruska JR; Kane AB
Cancer Res; 2007 Apr; 67(8):3637-45. PubMed ID: 17440075
[TBL] [Abstract][Full Text] [Related]
49. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
Attanoos RL; Thomas DH; Gibbs AR
Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
[TBL] [Abstract][Full Text] [Related]
50. Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway.
Wörthmüller J; Blum W; Pecze L; Salicio V; Schwaller B
Oncotarget; 2018 Nov; 9(91):36256-36272. PubMed ID: 30555628
[TBL] [Abstract][Full Text] [Related]
51. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
52. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
[TBL] [Abstract][Full Text] [Related]
53. The pathogenesis of mesothelioma.
Carbone M; Kratzke RA; Testa JR
Semin Oncol; 2002 Feb; 29(1):2-17. PubMed ID: 11836664
[TBL] [Abstract][Full Text] [Related]
54. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
[TBL] [Abstract][Full Text] [Related]
55. LRRN4 and UPK3B are markers of primary mesothelial cells.
Kanamori-Katayama M; Kaiho A; Ishizu Y; Okamura-Oho Y; Hino O; Abe M; Kishimoto T; Sekihara H; Nakamura Y; Suzuki H; Forrest AR; Hayashizaki Y
PLoS One; 2011; 6(10):e25391. PubMed ID: 21984916
[TBL] [Abstract][Full Text] [Related]
56. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
[TBL] [Abstract][Full Text] [Related]
57. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
58. Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos.
Gabrielson EW; Van der Meeren A; Reddel RR; Reddel H; Gerwin BI; Harris CC
Carcinogenesis; 1992 Aug; 13(8):1359-63. PubMed ID: 1323425
[TBL] [Abstract][Full Text] [Related]
59. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice.
Altomare DA; Menges CW; Pei J; Zhang L; Skele-Stump KL; Carbone M; Kane AB; Testa JR
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3420-5. PubMed ID: 19223589
[TBL] [Abstract][Full Text] [Related]
60. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.
Carbone M; Yang H
Clin Cancer Res; 2012 Feb; 18(3):598-604. PubMed ID: 22065079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
